Fig 1.
Abbreviations: LoP/R, Lopinavir/Ritonavir; HQ, Hydroxychloroquine; CA/LoP, Cephalosporin, Azithromycin, Lopinavir/Ritonavir; CA/HQ, cephalosporin, Azithromycin, Hydroxychloroquine.
Table 1.
Baseline characteristics, symptoms, comorbidities, vital signs, and initial laboratory indices of study cohorts before propensity score matching.
Table 2.
Baseline characteristics, symptoms, comorbidities, vital signs, and initial laboratory indices of Standard and CA/LOP group, CA/HQ group after propensity score matching.
Table 3.
Clinical outcomes before and after propensity score matching.
Table 4.
Adverse effects and drug switch percentage before propensity score matching.
Fig 2.
Kaplan-Meier curves regarding the three endpoints: Time to symptom resolution, time to viral clearance, and hospital stay duration, comparing CA/LoP vs standard group (A-C) and CA/HQ vs standard group (D-F). A-C: CA/LoP vs Standard group D-F: CA/HQ vs Standard group A, D: Time to Symptom resolution B, E: Time to viral clearance C, F: Hospital stay duration.
Table 5.
Associations of antibiotics and antiviral treatments with time to symptom resolution, time to viral clearance, and hospital stay duration in crude analysis, multivariable analysis, and propensity score matching analysis.
Standard therapy group is used as the reference.